CD206-Targeted Liposomal Myelin Basic Protein Peptides in Patients with Multiple Sclerosis Resistant to First-Line...

Area of Science:

• Neuroimmunology
• Demyelinating Diseases
• Drug Development

Background:

• Experimental autoimmune encephalomyelitis (EAE) is a model for multiple sclerosis (MS).
• CD206-targeted liposomal delivery of myelin basic protein (MBP) sequences (Xemys) previously suppressed EAE in rats.
• Patients with relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS) often require new therapies if first-line treatments fail.

Purpose of the Study:

• To assess the safety and tolerability of Xemys in patients with MS.
• To evaluate Xemys as a potential disease-modifying therapy for MS.
• To explore the effects of Xemys on clinical and MRI outcomes in MS patients.

Main Methods:

• A Phase I, open-label, dose-escalating study.
• 20 patients with RRMS or SPMS received weekly subcutaneous injections of Xemys.
• Clinical assessments, MRI, and serum cytokine levels were monitored.

Main Results:

• Xemys was safe and well-tolerated up to 900 μg.
• No significant changes in Expanded Disability Status Scale (EDSS) or T2 lesions were observed.
• A significant increase in active gadolinium-enhancing lesions was noted at weeks 7 and 10.

Conclusions:

• Xemys is safe and well-tolerated in MS patients.
• Further development of Xemys as an antigen-specific therapy for MS is supported.
• Observed changes in MRI lesions and cytokines suggest potential immunomodulatory effects.